London, UK, 11 December 2006: BioProgress plc (‘BioProgress’ or the ‘Company’) (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, today announces that it has agreed a new strategic partnership agreement with Uluru Inc, for the treatment of mouth ulcers using Uluru’s Oradisc™ technology, in the European, CIS and Middle Eastern markets.
